Enhanced formation of nitric oxide (NO) by both the constitutive and the inducible isoforms of NO synthase (NOS) has been implicated in the pathophysiology of a variety of diseases, including circulatory shock. Non-isoform-selective inhibition of NO formation, however, may lead to side effects by inhibiting the constitutive isoform of NOS and, thus, the various physiological actions of NO. S-Methylisothiourea sulfate (SMT) is at least 10-to 30-fold more potent as an inhibitor of inducible NOS (iNOS) in immunostimulated cultured macrophages (EC50, 6 ,AM) and vascular smooth muscle cells (EC50, 2 ,uM) than NG-methyl-L-arginine (MeArg) Moreover, therapeutic administration of SMT (5 mg/kg, i.p., given 2 hr after LPS, 10 mg/kg, i.p.) attenuates the rises in plasma alanine and aspartate aminotransferases, bilirubin, and creatinine and also prevents hypocalcaemia when measured 6 hr after administration of LPS. SMT (1 mg/kg, i.p.) improves 24-hr survival of mice treated with a high dose of LPS (60 mg/kg, i.p.). Thus, SMT is a potent and selective inhibitor of iNOS and exerts beneficial effects in rodent models of septic shock. SMT, therefore, may have considerable value in the therapy of circulatory shock of various etiologies and other pathophysiological conditions associated with induction of iNOS.
reversed by excess L-arginine in a concentration-dependent manner. SMT (up to 1 mM) does not inhibit the activity of xanthine oxidase, diaphorase, lactate dehydrogenase, monoamine oxidase, catalase, cytochrome P450, or superoxide dismutase. SMT is equipotent with MeArg in inhibiting the endothelial, constitutive isoform of NOS in vitro and causes increases in blood pressure similar to those produced by MeArg in normal rats. SMT, however, dose-dependently reverses (0.01-3 mg/kg) the hypotension and the vascular hyporeactivity to vasoconstrictor agents caused by endotoxin [bacterial lipopolysaccharide (LPS), 10 mg/kg, i.v.] in anesthetized rats. Moreover, therapeutic administration of SMT (5 mg/kg, i.p., given 2 hr after LPS, 10 mg/kg, i.p.) attenuates the rises in plasma alanine and aspartate aminotransferases, bilirubin, and creatinine and also prevents hypocalcaemia when measured 6 hr after administration of LPS. SMT (1 mg/kg, i.p.) improves 24-hr survival of mice treated with a high dose of LPS (60 mg/kg, i.p.). Thus, SMT is a potent and selective inhibitor of iNOS and exerts beneficial effects in rodent models of septic shock. SMT, therefore, may have considerable value in the therapy of circulatory shock of various etiologies and other pathophysiological conditions associated with induction of iNOS.
Nitric oxide (NO) is produced by a group of isoenzymes collectively termed NO synthases (NOSs) (1, 2) . NO derived from the constitutive isoform is a neurotransmitter in the central and peripheral nervous system (3) . NO generated by the constitutive isoform of NOS in the vascular endothelium (eNOS) is involved in the regulation of blood pressure and organ blood flow distribution and inhibits the adhesion of platelets and polymorphonuclear granulocytes to the endothelial surface (1, 2, 4) . Dysfunction of NO formation by the vascular endothelium is implicated in the pathogenesis of hypertension, hypercholesterolemia, diabetes mellitus, ischemia-reperfusion injury, angina pectoris, subarachnoid hemorrhage, and various forms of circulatory shock (5) (6) (7) (8) (9) (10) (11) . NO derived from eNOS also plays a protective role in endotoxininduced gastointestinal damage (12, 13) .
Another isoform of NOS (inducible NOS, iNOS) can be induced in various cells, including macrophages, by a variety of agents such as endotoxin (bacterial lipopolysaccharide, LPS), interleukin 1, tumor necrosis factor, and y-interferon (IFN-y). The cytotoxicity of NO from activated macrophages plays a key role in their antimicrobial activity (1, 2) . Enhanced formation of NO following the induction of iNOS contributes importantly to the circulatory failure (hypotension and vascular hyporeactivity to vasoconstrictor agents) in circulatory shock of various etiologies (14) (15) (16) (17) (18) (19) . Moreover, iNOS plays a role in the pathophysiology of a variety of other diseases, including diabetes and transplant rejection (20) (21) (22) (23) (24) (25) (26) (27) (28) . However, non-isoform-selective inhibition of NO formation may lead to side effects by inhibiting the constitutive isoform of NOS and, thus, the various physiological actions of NO. Thus, selective inhibitors of iNOS may well be of great therapeutic potential. Some L-arginine analogues show a limited isoform selectivity in their inhibition of NOS. For instance, NG-cyclopropyl-L-arginine, NG-nitro-L-arginine (NO2Arg), and its methyl ester (after hydrolysis) are more potent inhibitors of eNOS than of iNOS (29) (30) (31) (32) , whereas NG-methyl-L-arginine (MeArg), NG-amino-L-homoarginine, and NG-amino-L-arginine are equipotent inhibitors of both iNOS and eNOS (29) (30) (31) (32) . MeArg is the preferred L-argininebased NOS inhibitor for targeting iNOS in vivo or in vitro. Aminoguanidine and some related guanidines, however, are weaker inhibitors of eNOS than iNOS and, hence, are relatively selective as inhibitors of iNOS (33, 34) . Here we report that S-methylisothiourea sulfate (SMT) is a potent NOS inhibitor which is relatively selective for iNOS activity and exerts beneficial effects in rodent models of septic shock.
METHODS
Cell Culture. The mouse macrophage cell line J774.2 and rat aortic smooth muscle cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 3.5 mM L-glutamine and 10% fetal bovine serum (35, 36 -8 -7 -6 -5 -4 Inhibitor (log M) 10. 0.
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Inhibitor (log M) various inhibitors on nitrite production, agents were added to the cells either 5 min before or 6 hr after LPS. Nitrite production, an indicator of NO synthesis, was measured by the Griess reaction (35, 36) . Cell respiration, an indicator of cell viability, was assessed by the mitochondrial-dependent reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan (35, 36 (17, 18) . After 180 min, SMT (0.01-3 mg/kg, i.v.) was injected. For comparison, the effect of MeArg, NO2Arg methyl ester, and aminoguanidine were also investigated. (Fig. 1 a and b) . SMT is a more potent inhibitor of iNOS than any other known inhibitor of NOS, including NG-amino-L-arginine, aminoguanidine, NO2Arg, or its methyl ester, in both cell types studied (Fig. la) . SMT is a direct inhibitor of the activity of iNOS and does not interfere with the induction of iNOS, for (i) the inhibitory effect of SMT on nitrite formation of LPS-activated macrophages remains unchanged when SMT is given after the stimulus of induction (Fig. lc) and (ii) SMT also inhibits the formation of L-citrulline from L-arginine in homogenates of lungs obtained from rats treated with LPS in the absence of Ca2+ (Fig. ld) . This L-citruiline formation is due to iNOS activity (17) . The effect ofSMT is attenuated by excess L-arginine in the culture medium (Fig. le) , suggesting that SMT is a competitive inhibitor of iNOS activity at the L-arginine site. SMT itself is not cytotoxic. Indeed, it prevents the NO-mediated cytotoxic effect of LPS in cultured macrophages (Fig. lf) which is due to inhibition of mitochondrial respiratory-chain enzymes (39) .
LPS-Induced Changes in
While SMT is more potent than MeArg on iNOS activity, SMT is equipotent with MeArg in inhibiting eNOS activity in endothelial cell homogenates (Fig. lg) . This suggests that SMT has a relative selectivity toward iNOS when compared with MeArg or other L-arginine-based NOS inhibitors (29) (30) (31) (32) . When compared with aminoguanidine, another non- arginine-based NOS inhibitor with selectivity toward iNOS (20, 21) , SMT is 10-50 times more potent as an inhibitor of iNOS activity in LPS-treated J774.2 macrophages and in lung homogenates obtained from rats treated with LPS ( Fig. 1 a  and d ). In addition, SMT is =100 times more potent than aminoguanidine on eNOS activity ( Figs. lg and 2a ; see also refs. 20 and 21) . This suggests that SMT is almost as selective as aminoguanidine as an inhibitor of iNOS activity, while it has a lower EC50 for iNOS activity in vitro.
The effect of SMT appears to be specific for NOS, since it does not inhibit (up to 1 mM) the activity of XO, diaphorase, lactate dehydrogenase, monoamine oxidase, catalase, cytochrome P450, or superoxide' dismutase (Fig. lh) .
Hemodynamic Effects of SMT in the Rat. The pressor effects of moderate doses of SMT in control anesthetized rats are similar to those of MeArg and weaker than those of NO2Arg methyl ester. This is inmaccord with the in vitro eNOS data. However, in contrast to the arginine analogues, the pressor responses afforded by SMT are much greater in rats treated with LPS than in control rats. Thus, SMT is a more potent pressor agent than MeArg in septic rats (Fig. 2 b), indicating that SMT is the more potent inhibitor of iNOS activity in vivo. Most notably, injection of SMT (3 mg/kg) into LPS-treated rats causes a prompt restoration ofthe blood pressure to pre-LPS levels (Fig. 2c) . In addition, SMT inhibits iNOS activity measured in homogenates of lung from rats treated with LPS (Fig. 2d) . Aminoguanidine, in normal rats, did not markedly increase blood pressure even at a dose as high as 45 mg/kg. However, in rats treated with LPS, the same dose of aminoguanidine caused only a partial restoration of the blood pressure (Fig.  2a) . This observation, together with the facts that (i) 'the vascular actions of aminoguanidine have a slow onset (40) and (ii) the drug inhibits a variety of other enzymes, suggests that SMT may have advantages over aminoguanidine in targeting iNOS activity in vivo.
LPS treatment for 6 hr increases the plasma levels of alanine and aspartate aminotransferases and ofbilirubin (Fig.  3 a-c) . Administration of SMT 2 hr after LPS prevents'these changes, suggesting that SMT protects against the LPSinduced (and NO-mediated) liver damage (Fig. 3 a-c) . These results do not support a previous proposal (41) that iNOS plays a protective role in hepatic dysfunction in sepsis. LPS also causes an impairment of renal function, as indicated by an increase in plasma creatinine (Fig. 3d) . Inhibitors ofeNOS are known to exaggregate this renal damage by causing further vasoconstriction and glomerular thrombosis (42) , whereas SMT causes a significant improvement of this parameter of renal function (Fig. 3d) , possibly by increasing MAP and, hence, perfusion pressure to the kidney. SMT also protects against the hypocalcemia associated with ehdotoxin shock (Fig. 3e) . However, it does not enhance the neutropenia caused by LPS (Fig. 3f) , suggesting either' that SMT only slightly affects eNOS activity in vivo or that any potential inhibition of eNOS activity by SMT is not sufficient to cause an enhanced adhesion of neutrophils to the endothelium. When given to control rats, SMT (up to 50 mg/kg) has no effect on any of the above parameters, suggesting that acute administration of a high dose of SMT does not-cause liver or kidney dysfunction or neutropenia (Fig. 3) .
Effect'of SMT on 24-hr Survival in Mice Treated with LPS.
In mice injected with a high' dose of LPS (60 mg/kg, i.p.), SMT (1 mg/kg) improves 24-hr survival from 8.3% to 50%6 (P < 0.05) (Fig. 4) . We speculate that the selective inhibition by SMT on iNOS activity is responsible for this effect.
Conclusions. Here we demonstrate that SMT is a more potent inhibitor ofiNOS activity than any ofthe yet described NOS inhib'itors. SMT protects rats against the circulatory failure and organ dysfunction caused by endotoxin and improves survival in a murine model of septic shock. SMT, or other iNOS-selective inhibitors, are likely to have fewer side effects which are related to the inhibition of eNOS, such as excessive vasoconstriction and organ ischemia (1, 2, 4), increased platelet and neutrophil adhesion and accumulation (1, 2, 4, 43) , and microvascular leakage (43) . We speculate Pharmacology: Szab6 et al.
Proc. Natl. Acad. Sci. USA 91 (1994) that SMT will have advantages over L-arginine-based NOS inhibitors (e.g., MeArg) in the therapy of circulatory shock of various etiologies (14) (15) (16) (17) (18) (19) . These compounds may also be of therapeutic benefit in other diseases associated with iNOS induction, such as chronic arthritis (22, 23) , chronic inflammation (24) , diabetes (20, 21) , transplant rejection (26) , some forms of chronic inflammatory reactions of the central nervous system (25) , and some forms of cancer (27, 28) .
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